Analysis of hydration and antiemetics policies in preventing cisplatin-related gastrointestinal and renal toxicities in low-risk human papillomavirus positive-oropharyngeal cancer (HPV+OPC) patients undergoing chemoradiation in De-ESCALaTE trial.

Anthony Kong,Pankaj Mistry,Mererid Evans,Andrew G. J. Hartley,Tessa Fulton-Lieuw,David Ceri Jones,Matthew Dalby,Alastair Gray,Bernadette Foran,Mehmet Sen,Lorcan O’Toole,H. Al-Booz,K. Dyker,Rafael Moleron Mancebo,Stephen Whittaker,S. Brennan,Audrey Cook,Matthew Griffin,Janet A. Dunn,Hisham Mehanna

Analysis of hydration and antiemetics policies in preventing cisplatin-related gastrointestinal and renal toxicities in low-risk human papillomavirus positive-oropharyngeal cancer (HPV+OPC) patients undergoing chemoradiation in De-ESCALaTE trial.

2019

6076Background: The De-ESCALaTE trial confirmed the superiority of cisplatin over cetuximab in combination with radiotherapy for the treatment of low risk human papillomavirus positive oropharyngea...

Keywords:

Cancer
Oncology
Cisplatin
Pathology
Internal medicine
Human Papillomavirus Positive
Medicine
Radiation therapy
Cetuximab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations